AECOPD (n = 84) | Acute HF (n = 143) | Non-HF, non-COPD (n = 87) | P * | |
---|---|---|---|---|
Age (years) | 69 ± 9 | 75 ± 11 | 73 ± 18 | <0.001 |
Male sex | 35 (42%) | 90 (63%) | 39 (45%) | 0.002 |
BMI (kg/m2) | 24 ± 6 | 27 ± 6 | 29 ± 9 | 0.005 |
Heart rate (beats/min) | 97 ± 18 | 92 ± 26 | 91 ± 22 | 0.107 |
MAP (mmHg) | 102 ± 18 | 104 ± 21 | 99 ± 16 | 0.546 |
Peripheral edema | 31 (37%) | 77 (54%) | 16 (18%) | 0.014 |
NYHA class IV vs. II-III | 47 (56%) | 65 (46%) | 24 (28%) | 0.127 |
LVEF (%) | 60 (50–60)a | 40 (30–55) | 60 (54–60)a | <0.001 |
FEV1% of predicted | 39 ± 17 | n.ab | n.ab | |
FEV1/FVC (%) | 47 ± 15a | n.a b | n.ab | |
Current smoker | 28 (33%) | 30 (21%) | 27 (31%) | 0.039 |
Diabetes | 9 (11%) | 43 (30%) | 16 (18%) | 0.001 |
Chronic heart failure | 9 (11%) | 87 (61%) | 5 (6%) | <0.001 |
Coronary artery disease | 23 (27%) | 78 (55%) | 10 (12%) | <0.001 |
Hypertension | 26 (31%) | 69 (48%) | 25 (29%) | 0.011 |
COPD | 84 (100%) | 61 (43%) | 10 (12%) | <0.001 |
Beta-blocker | 31 (37%) | 89 (62%) | 19 (22%) | <0.001 |
ACEi/ARB | 27 (32%) | 87 (61%) | 25 (29%) | <0.001 |
Diuretic therapy | 33 (39%) | 104 (73%) | 23 (27%) | <0.001 |
K+ (mmol/L) | 4.3 ± 0.5 | 4.4 ± 0.6 | 4.2 ± 0.5 | 0.667 |
Na+ (mmol/L) | 138 (134–140) | 139 (136–141) | 138 (136–140) | 0.050 |
eGFR (mL/min) | 82 ± 20 | 61 ± 24 | 87 ± 31 | <0.001 |
CRP (mg/L) | 26 (6–50) | 13 (5–35) | 16.5 (1–95) | 0.019 |
hs-TnT (ng/L) | 18 (9–28) | 38 (22–75) | 9 (3–23) | <0.001 |
NT-proBNP (pg/mL) | 379 (171–1010) | 3600 (1601–8396) | 280 (88–1293) | <0.001 |
Copeptin (pmol/L) | 8.8 (5.2–19.7) | 22.2 (10.2–47.9) | 8.3 (4.3–18.2) | <0.001 |